Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisolone in Post-COVID Diffuse Lung Disease
NCT04657484Completed
- Sponsor
- Post Graduate Institute of Medical Education and Research
- Start
- Dec 2020
- Primary completion
- Sep 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of prednisolone in interstitial lung disease (ILD) (2 arms), sponsored by Post Graduate Institute of Medical Education and Research. Primary endpoint: Proportion of subjects with a complete radiologic response at 6 weeks. Started Dec 2020; status: completed.
02
Drugs
prednisolone
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT04657484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04657484.